TLX-66 is under clinical development by Telix Pharmaceuticals and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TLX-66’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLX-66 overview
TLX-66 is under development for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, juvenile myelomonocytic leukemia (JMML), refractory acute myeloid leukemia and hematopoietic stem cell transplantation. It is administered as intravenous infusion. The drug is a radionuclide drug conjugate (RDC) which contains murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90. It acts by targeting CD66b expressing cancer cells.
It was also under development for myelodysplasia, multiple myeloma, chronic myeloid leukemia and systemic AL amyloidosis.
Telix Pharmaceuticals overview
Telix Pharmaceuticals (Telix) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals. It utilizes targeted radiation technology to target small molecule or antibody that binds to tumor cells. The company’s pipeline products include TLX592, TLX591-CDx and TLX591 radio antibody-drug conjugate (rADC) directed at PSMA that targets prostate cancer; TLX250-CDx and TLX250 for kidney cancer; TLX101-CDx and TLX101 treat brain cancer; TLX66-CDx and TLX66 for bone marrow conditioning; and TLX300 and TLX300-CDx. It offers Illuccix, an imaging agent targeting men with prostate cancer. Telix’s brands include RADmAb, Zircaix, Scintimun and Pixclara. The company operates its offices in Japan, Australia, Canada, the US and Switzerland. Telix is headquartered in North Melbourne, Victoria, Australia.
For a complete picture of TLX-66’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
